Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Bicycle Therapeutics plcNASDAQ: BCYC
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items outflow shrinks to $0
Q1 FY2026 other non-cash items was $0, compared with $36.88K a year earlier. Trailing-twelve-month other non-cash items was -$30.75M.
Context
- Other non-cash items amounted to 0.0% of revenue in FY2025, down 6.4 pp from a year earlier.
- Other non-cash items increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other non-cash items holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$7.69M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (2.26M) | -316.6% |
| FY2023 | 2023-12-31 | 1.04M | +136.2% |
| FY2022 | 2022-12-31 | 442K | -79.3% |
| FY2021 | 2021-12-31 | 2.14M | — |
Other Non-Cash Items vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 other non-cash items of $30.75M is the 3rd largest of the 10 companies compared; the peer median is $1.66M.
- Its year-over-year change of +1982.5% is the highest of 9, against a peer median of +38.6%.
- Other non-cash items amounts to 48.4% of revenue for BCYC, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $217.51M | +1659.6% | — | 2198.6% | |
| LTM Dec 2025 | $130.61M | — | — | 112.7% | |
| LTM Mar 2026 | $30.75M | +1982.5% | — | 48.4% | |
| LTM Mar 2026 | $5.11M | +509.3% | — | — | |
| LTM Mar 2026 | $4.55M | -40.8% | — | 5.2% | |
| LTM Mar 2026 | $2.88M | -86.0% | +16.2% | 3.6% | |
| LTM Mar 2026 | $2.24M | -281.4% | -21.4% | 3.9% | |
| LTM Mar 2026 | $1.69M | +118.0% | — | 2.4% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.66M | +167.4% | -60.9% | — |
| LTM Mar 2026 | $585K | -85.3% | — | — | |
| Peer median (excluding BCYC) | $1.66M | +38.6% | -21.4% | 4.5% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.17M | 6.42M |
| Deferred Income Tax | (1.67M) | (4.98M) | 3.31M | (5.23M) | (850K) |
| Stock-Based Compensation | 12.08M | 26.78M | 32.48M | 38.08M | 39.46M |
| Change in Working Capital | 38.07M | 672K | 76.66M | (33.46M) | (75.75M) |
| Accounts Receivables | 4.54M | (11.35M) | (1.2M) | (11.95M) | 2.89M |
| Inventory | (4.79M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 2.56M | 8M | 3.1M | (6.87M) |
| Other Working Capital | 37.12M | 9.46M | 69.86M | (24.61M) | (71.77M) |
| Other Non-Cash Items | 2.14M | 442K | 1.04M | (2.26M) | 0 |
| Operating Cash Flow | (14.79M) | (86.11M) | (60.63M) | (164.72M) | (249.68M) |
| Capital Expenditures | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 5.49K |
| Investing Cash Flow | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.35M) |
| Debt Repayment | 15M | 0 | 0 | (31.91M) | 0 |
| Common Stock Issued | 298.54M | 5.7M | 249.35M | 544.13M | 37.09K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.18M | 989K | 682K | 7.53M | (168.09K) |
| Financing Cash Flow | 320.73M | 6.69M | 250.03M | 519.75M | (131K) |
| Effect of Forex Changes | (1.21M) | (1.12M) | 1.35M | (694K) | 804K |
| Net Change in Cash | 302.69M | (99.53M) | 187.82M | 353.1M | (251.35M) |
| Free Cash Flow | (16.82M) | (105.1M) | (63.56M) | (165.96M) | (252.61M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.